human DIPg tumors. However, following the direct transplantation method all tumors proved to be composed of murine and not of human cells. This is in contrast to the indirect method that included initial in vitro culture and resulted in xenografts comprising human cells. Of note, direct injection of cells obtained postmortem from the pons and frontal lobe of human brains not affected by cancer did not give rise to neoplasms. The murine pontine tumors exhibited an immunophenotype similar to human DIPg, but were also positive for microglia/macrophage markers, such as CD45, CD68 and CD11b. Serial orthotopic injection of these murine cells results in lethal tumors in recipient mice. Direct injection of human DIPg cells in vivo can give rise to malignant murine tumors. This represents an important caveat for xenotransplantation models of DIPg. In contrast, an initial in vitro culture step can allow establishment of human orthotopic xenografts. The mechanism underlying Abstract Diffuse intrinsic pontine glioma (DIPg), with a median survival of only 9 months, is the leading cause of pediatric brain cancer mortality. Dearth of tumor tissue for research has limited progress in this disease until recently. New experimental models for DIPg research are now emerging. To develop preclinical models of DIPg, two different methods were adopted: cells obtained at autopsy (1) were directly xenografted orthotopically into the pons of immunodeficient mice without an intervening cell culture step or (2) were first cultured in vitro and, upon successful expansion, injected in vivo. Both strategies resulted in pontine tumors histopathologically similar to the original e. Hulleman, M. Monje and T. Wurdinger contributed equally.
Introduction
Diffuse intrinsic pontine glioma (DIPg) is a devastating brain cancer affecting mainly children [19, 22] . Compared to other brain malignancies, DIPg carries the worst prognosis; the majority of affected children die within 1 year from diagnosis [10, 12] . DIPg is also one of the pediatric tumors that has been the least investigated in laboratories, due to a lack of primary tissue available for research and the paucity of robust preclinical models. We have established autopsy protocols to develop experimental models of DIPg and to investigate its biology [7, 30] .
recent studies have shown that DIPg is molecularly distinct from adult high-grade gliomas [35, 49] . Although DIPg shares recurrent aberrations in histone 3 genes with supratentorial pediatric gliomas, they are molecularly distinct tumors [42, 43, 49] . DIPg is characterized by unique hallmarks including a remarkable spatiotemporal specificity (occurring in the ventral pons during mid-childhood) and a diffuse growth pattern. As the disease progresses, DIPg often invades the cerebellum and even supratentorial brain regions, such as the thalamus, lateral ventricles and cerebral cortex [54] . DIPg infiltrative growth and the delicate anatomical location where it arises preclude surgical resection. The pontine microenvironment at mid-childhood may be of paramount importance in the biology, pathogenesis and infiltrative nature of DIPg [6, 30] . To find a cure for this disease, it is critical to identify the microenvironmental and genetic factors that allow the tumor to spread throughout the brainstem and the entire brain.
Here, we present data showing that direct injection of human DIPg cells obtained from postmortem tissue produced tumors composed exclusively of murine cells, while injection of human DIPg cells, obtained at autopsy but first cultured in vitro, gave rise to human xenografts. In comparison, direct injection of cells obtained postmortem from the pons and frontal lobe of human brains not affected by cancer did not give rise to murine neoplasms. The cells of these induced murine neoplasms exhibited immunocytochemical markers consistent with DIPg and also with the microglia/macrophage phenotype.
Materials and methods

Tissue donors
All tumor samples were post-treatment autopsy specimens from VU University Medical Center Amsterdam (VUMC) (The Netherlands), Stanford University (SU) and Children's National Medical Center (CNMC) in Washington DC (United States). Patients were included if they had classic DIPg MrI findings and clinical presentation. All parents signed informed consent forms for the use of biological material after autopsy for research purposes and the appropriate institutional review board (IrB) approved all procedures. The autopsy protocols have been previously reported [7, 30] . Patients' clinical characteristics are summarized in Table 1 and supplementary Table 1 . For clarity, the suffix "h" for human and "m" for murine will be used in front of all patients and cell lines and tumor sample names. All human patients affected by DIPg were treated with radiotherapy and/or chemotherapy, with the exception of patient h-SU-DIPg-I, who received only minimal treatment for the tumor [30] .
The human donor brains used for control tissue were obtained from the National Development and research Institute (NDrI) (http://www.ndri.org). The donors were males not affected by brain cancer; they were of age 53 (cause of death: cardiac arrest) and age 59 (cause of death: respiratory disease); the samples collected were named h-SU-NDrI-2 and h-SU-NDrI-3, respectively. The deathautopsy interval was 12.5 h for h-SU-NDrI-2 and 5.56 h for h-SU-NDrI-3.
Direct and indirect xenotransplantation methods
For the direct transplantation method, immediately after rapid brain autopsy of four DIPg patients (h-VU-DIPg-3, -4 and -5 and h-CNMC-D1; mean postmortem delay was 3.4 h) [7] , a single cell suspension was prepared from pontine tissue macroscopically infiltrated by tumor. Tumor material was cut into 0.5 cm 3 pieces with a sterile scalpel and mechanically dissociated using a 100 μm strainer and resuspended in Opti-MeM medium or, for injection subcutaneously, in Matrigel (BD biosciences) diluted 1:3 in phosphate-buffered saline (PBS).
The indirect method, previously described [30] , also followed rapid brain autopsy of DIPg patients (h-SU-DIPg-VI; postmortem delay was 2 h). Briefly, for chemical dissociation, minced tissue was placed in Hepes-HBSS with DNaseI (250 U/ml) and collagenase type IV (1 mg/ml) at 37 °C on a Nutator (Fisher Scientific). Cells were then further mechanically dissociated using 100, 70 and 40 μm strainers in series. Next, a 30 % sucrose gradient and the ACK lysis buffer (Invitrogen) were employed to deplete myelin and red blood cells, respectively. Finally, the single cell suspension was cultured in serum-free tumor stem media (TSM) consisting of Neurobasal media (-A) (Invitrogen), B27 (-A) (Invitrogen), human-basic FgF (20 ng/ml; Shenandoah Biotech), human egF (20 ng/ml; Shenandoah Biotech), human PDgF-AA and -BB (20 ng/ml; Shenandoah Biotech), and heparin (10 ng/ml) [30] .
Primary tumor cell culture
Human SU-DIPg-VI cells were cultured in TSM, as described above. After extraction from subcutaneous tumors (m-VU-DIPg-3 and -5) and from pons xenograft (CNMC-D1 cells), murine cells were cultured in NeuroCult Basal Medium (StemCell Technologies) supplemented with murine egF (20 ng/ml; Shenandoah Biotech), murine FgF (20 ng/ml; Shenandoah Biotech) and heparin (10 ng/ml).
Stereotactic DIPg cell injection
All animal experiments were approved and performed according to the guidelines of the VU University ethical and Scientific Committee on Animal experiments, Stanford University Institutional Care and Use Committee, and CNMC Institutional Animal Use and Care Protocols (#01429, #01335).
At the VU, non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) mice and female athymic nude (age 6-12 weeks; Harlan), at Stanford NOD-SCIDIl2 gamma chain-deficient (NSg) mice (age P1-5 and 6-12 weeks; The Jackson laboratory) and at the CNMC nude mice J:NU (age P-5, The Jackson laboratory) were kept under specific pathogen-free conditions in air-filtered cages and received food and water ad libitum. We have previously reported the procedures used for stereotactic tumor cell transplantation both in adult [8] and in pup [30] mice and for tumor cell injection subcutaneously [8] . For surgeries in adult mice, 1 × 10 6 human DIPg cells/5μl or 1 × 10 5 murine VU-DIPg-3 and -5 cells/5μl were injected in the pons or striatum of immunodeficient mice. For adult mice, the stereotactic coordinates used to target the pons were: 0.8 mm posterior to lambda, 1 mm lateral to the sagittal suture and 5 mm deep; and to target the striatum: 2 mm anterior to bregma, 0.5 mm lateral to the sagittal suture and 2 mm deep. For pup surgeries, 4 × 10 4 cells/5μl were injected in the IV ventricle, using the following coordinates: 3 mm posterior to lambda, 0 mm lateral to the sagittal suture and 3 mm deep.
Immunohistochemical staining
Immunohistochemistry (IHC), immunofluorescence (IF), and fluorescence in situ hybridization (FISH) were performed on 5 μm tissue sections of paraffin-embedded (IHC and FISH) or fresh-frozen (IF) human and murine DIPg tumor samples. IHC was performed as previously described [7] . The following antibodies were used: NeuN (mouse monoclonal, 1:1,600, Millipore), gFAP (rabbit polyclonal, 1:300, Dako), Synaptophysin (mouse monoclonal, 1:150, Dako), CD45 (mouse monoclonal, [38] . The chromosome enumeration probe 1 (CeP1 Spectrum Orange Probe, diluted 1:10 in uni-44 buffer, Abbott Molecular, Abbott Park, Illinois, USA) was used. Hybridization was performed overnight at 37 °C.
Karyotyping
Metaphase preparations of m-VU-DIPg-3 and -5, m-CNMC-D1 and h-SU-DIPg-VI cells were obtained by standard cytogenetic procedures of mitotic arrest, hypotonic shock and cell fixation. Metaphase cells were stained by standard g-banding methodology and imaged using a Zeiss Axioskop 20 microscope with 100× plan apochromatic objective and a CytoVision imaging system (leica Microsystems, USA).
Array-comparative genomic hybridization and Sanger sequencing of exons
Human VU-DIPg-3 and -5 somatic tumor DNA were isolated from the original pontine tumor. Non-somatic DNA was isolated from areas far away from the original pontine tumor (temporal lobe) with no macroscopic signs of intraparenchymal tumor growth. Cases were independently reviewed by a senior neuropathologist (PW) according to the World Health Organization (WHO) guidelines. Histologically, both tumors were labeled as glioblastoma (gBM) ( Table 1 ). Control murine DNA was isolated from corresponding nude or SCID mice. DNA was isolated from fresh-frozen tissue using an all prep DNA/rNA isolation kit (Qiagen). Samples were labeled and hybridized on human and murine array-comparative genomic hybridization (aCgH) oligo Microarray 4 × 180k (Agilent Technologies, Palo Alto, CA), as previously described [24] . Image acquisition of the Agilent arrays was performed using the Agilent DNA Microarray scanner g2505C, and image analysis was performed using Feature extraction software version 10.5.1.1 (Agilent Technologies). Amplifications of egFr, PTeN and PDgFr-α were analyzed by verifying the intensity of hybridized probes in the genomic regions of these genes.
exons of interest on H3F3A, HIST1H3B and PI3KCA (H1047r/l and e542K) were sequenced using Sanger fluorescent sequencing after amplification by polymerase chain reaction using standard methods. The primers were designed using primer BlAST from NCBI (supplementary Table 2 ). PCr products were directly sequenced using BigDye ® Terminator v3.1 Cycle Sequencing Kit (life technologies) and analyzed by a genetic analyzer (Applied Biosystems). For the murine samples VUMC-DIPg-3, sequencing of the H3F3A region of interest repetitively exhibited decrease in signal, rendering chromatogram analysis more difficult. Sequencing of this region was repeated in three independent experiments, all exhibiting normal (wild type) reads.
DNA fingerprinting
Short tandem repeat (STr) analysis was performed according to the manufacturer's protocol (PowerPlex 18D system, Promega). The STr fingerprint for h-SU-DIPg-VI control cortex is reported in supplementary Table 3 .
Flow cytometry
After in vitro culture, h-SU-DIPg-VI and m-CNMC-D1 cells were enzymatically dissociated as previously described [30] , and subcutaneous m-VU-DIPg-3 and -5 tumors were mechanically dissociated as described above. The following antibodies were incubated for 1 h: PerCPCy5.5 anti-mouse H-2K d , Pe anti-human HlA-A,B,C, Brilliant Violet421™ anti-mouse CD45 (all by Biolegend) and Pe-Cyanine7 anti-mouse and human CD11b (eBioscience). Cells were gated on the basis of forward-and sidescatter profiles, and live/dead discrimination was obtained with 7-amino-actinomycin D (7-AAD) (DAPI) or propidium iodide. Flow cytometry was performed using a FACS Aria II (BD Biosciences). Data were analyzed with FlowJo software.
Results
DIPg xenografts resemble the original human neoplasm histologically
To establish xenograft DIPg models, we used early postmortem autopsy protocols at the VU [7] and at Stanford University School of Medicine [30] . While at the VU a direct transplantation strategy was adopted, at Stanford human DIPg cells were first cultured in vitro and subsequently, upon successful expansion, injected in vivo (indirect method) (Fig. 1a) . In the direct transplantation method, postmortem DIPg tissue (h-VU-DIPg-3, -4 and -5) was immediately dissociated using rapid mechanical mincing and straining, without chemical processing of the sample or myelin depletion. The single cell suspension was directly injected subcutaneously (10 × 10 6 cells/100 μl/flank) and into the brain (pons and striatum; 1 × 10 6 cells/5 μl) of immunodeficient mice (n = 3/patient) (Fig. 1a, left panel) . In the indirect method, postmortem DIPg tissue (h-SUDIPg-VI) was dissociated enzymatically and the single cell suspension was cultured and expanded in vitro. Once neurospheres formed and expanded in vitro, cells were enzymatically dissociated and injected in the pons of NSg pups (Fig. 1a, right panel) .
Neither the direct nor indirect method resulted in subcutaneous tumor growth. Mice that received direct cell injection into the pons were killed due to neurological symptoms after 3, 6 and 9 months for the h-VU-DIPg-5, -3 and -4 xenografts, respectively. Necropsy analysis showed that human DIPg cells, injected directly into the pons, gave rise to tumors in three out of three autopsy cases (transplant generation 1); only for one autopsy case, h-VU-DIPg-3, tumor developed in the striatum (transplant generation 1). Human SU-DIPg-VI xenografts produced neurological symptoms after approximately 6 months.
Histologically, all tumors showed characteristics of the original human DIPg tissue including diffuse growth pattern, a hallmark of DIPg ( Fig. 1b; supplementary Fig. 1a-j) . Human DIPg tumors are highly heterogeneous [5, 34] ; m-VU-DIPg-3 and -5 resembled the small cell component observed in the corresponding h-VU-DIPg-3 and -5 tumors ( Fig. 1c; supplementary Fig. 1 ). Human VU-DIPg-3 and -5 presented perivascular growth, as did m-VU-DIPg-3 and -5 (supplementary Fig. 1b, d, f, g, l) . leptomeningeal spread in human DIPg is often detected at recurrence [44] and it was found both in h-VUMC-DIPg-5 and in m-VU-DIPg-3 and -5 ( Fig. 1b; supplementary Fig. 1c, f, i ). Perineuronal satellitosis [30] was also found both in the h-VUMCDIPg-3 and -5 and in the m-VUMC-DIPg-3 and -5 (supplementary Fig. 1h ). Tumor invasion in the skull bone was found after direct xenotransplantation of h-VU-DIPg-5 cells in the murine pons (supplementary Fig. 1k ). Of note, after m-VU-DIPg-3 and -5 were transplanted subcutaneously and thereafter in the murine pons, along with the diffuse tumor spread, areas of more compact growth were also detected (supplementary Fig. 1g ).
To establish VU-DIPg-3, -4 and -5 mouse models and given the low in vitro proliferation rate of VU-DIPg-3, -4 and -5 cells, serial tumor transplantations were performed. Once mice showed neurological symptoms; the brain was harvested and affected areas were resected using sterile instruments. A single cell suspension was prepared (mechanical dissociation) and cells were re-injected into the pons of nude mice (transplant generation 2; n = 3) and subcutaneously in Matrigel (n = 2). This time, tumors developed both subcutaneously and in the pons for m-VUDIPg-3 and m-VU-DIPg-5 within 3 weeks post-injection (Fig. 1a, left panel) , while no tumor growth could be detected for m-VU-DIPg-4 9 months post-injection. Via serial transplantation in nude mice, the m-VU-DIPg-3 and -5 models were established. For subsequent experiments, m-VU-DIPg-3 and -5 cells were first expanded subcutaneously and thereafter injected in the murine pons (transplant generations 3-10).
Direct injection of human DIPg cells in the murine pons gives rise to murine tumors
The tumors that developed after direct injection of h-VUDIPg-3, -4 and -5 cells into the murine pons comprised murine instead of human cells (Fig. 2a-d, g ). Conversely, h-SU-DIPg-VI cells injected in the pons after in vitro passaging gave rise to human tumors (Fig. 2e, f) .
Several lines of evidence were used to verify that the m-VU-DIPg-3 and -5 tumors were entirely composed of murine cells. For the purpose of comparison, we used tissue of the h-e98-FM adult glioblastoma-derived pontine xenografts, known to be of human origin [8] . The exclusive presence in the normal murine karyotype of telocentric chromosomes is a major morphologic distinction from the human karyotype, which has no true telocentric chromosomes. Additionally, mouse and human chromosomes are readily separable by their distinct g-band patterns and their normal diploid number, 40 and 46, respectively. Analysis of m-VU-DIPg-3, -5 and m-CNMC-D1 cells demonstrated only chromosomes of obvious murine origin by telocentric morphology and banding pattern. No human chromosomes were observed. Conversely, h-SU-DIPg-VI demonstrated human chromosomes only, as assessed by morphology and banding pattern ( Fig. 2b; supplementary Fig. 2 Next, we performed IHC employing antibodies raised against specific human or murine antigens. First, m-VUDIPg-3 and -5 tumors were negative for human Vimentin, in contrast to h-e98-FM tumor tissue (Fig. 2c) . Second, Ki67 antibodies directed specifically against the human antigen did not react in the m-VU-DIPg-3 and -5 tissues, whereas Ki67 directed against the mouse antigen did react, again in contrast to h-e98-FM tumor tissues (Fig. 2d) .
Further, cross species hybridization of m-VU-DIPg-3 and h-VU-DIPg-3 on both human and murine aCgH platforms led to a clear decrease in the amount of DNA hybridization on the arrays of the opposite species (supplementary Fig. 3 ) and neither platforms showed an analyzable profile, suggesting that no large somatic human sequences were retained in the murine tumor. After correction for species-specific location of alleles on the genome, hybridization of m-VU-DIPg-3 DNA on the proper platform showed no corresponding gains and losses between mouse and human tumors (Table 2 ). In addition, via exon sequencing the presence of known DIPg mutations and amplifications was analyzed both in the human and murine tumors. The only aberration detected in the human VU-DIPg-3 and 5 (H3F3A K27M) was not present in the corresponding murine tumors (Table 2) .
Human SU-DIPg-VI xenograft tissue revealed Human Nuclei staining and human Vimentin staining (Fig. 2e, f , upper panels). When analyzed by flow cytometry, h-SUDIPg-VI cells cultured in vitro only exhibited, as expected, 99 % positivity to HlA (marker for the human major histocompatibility complex) and no cell positivity for H-2K d (marker for the murine major histocompatibility complex in the immunodeficient mice strains used in this study) (Fig. 3e, right panels) . These data indicate that human DIPg cells, when first cultured in vitro, engraft in the murine brain and give rise to tumors of human origin. The h-SU-DIPg-VI cells as well as the h-SU-DIPg-VI xenograft harbored the H3F3A K27M mutation ( Table 1) .
Development of murine neoplasms using the direct transplantation method was observed independently at two institutions (at the VUMC and the CNMC). At the CNMC, human DIPg cells gave rise to a murine tumor, named m-CNMC-D1. Murine CNMC-D1 cells were negative both for Human Nuclei and human Vimentin staining (Fig. 2e, f , lower panels). DNA fingerprinting was performed on DNA obtained from m-VU-DIPg-3, -5, m-CNMC-D1, h-SUDIPg-VI cells and from a tail biopsy of an NSg mouse (m-DNA-CTrl). On the gel, human STr were identified by bands lower than 500 base pairs (bp); while h-SUDIPg-VI and h-DNA-CTrl showed a clear band pattern lower than 500 bp, no bands lower than 500 bp was identified for any of the murine samples (Fig. 2g) . Next, m-VUDIPg-3, -5 and m-CNMC-D1 cells were analyzed by flow cytometry; no HlA positive cells could be detected, while 93, 94 and 12 % of the cells were positive to H-2K d , respectively (Fig. 3e, left and central panels) .
To test if this phenomenon could have been caused by cells derived from apparently normal human brain tissue rather than from tissue affected by DIPg, we collected postmortem samples from the pons and frontal lobe of two patients not affected by brain cancer. We used the exact same extraction, tissue dissociation and direct transplantation method employed for human DIPg tissue. NSg mice were injected subcutaneously or in the pons or in the (Fig. 2h) . Taken together, these data indicate that human DIPg cells derived from tissue collected at autopsy and injected directly into the pons of immunodeficient mice, but not after in vitro passaging, induce lethal murine brain tumors.
Murine tumors are positive both for immunomarkers seen in DIPg and for microglia/macrophage markers We then set out to characterize the cell identity of these pontine murine tumors. By analyzing both human and murine healthy pontine tissue at different ages, our group previously identified a specific cell population present uniquely in the ventral pons and at mid-childhood (corresponding to P21 in mice). Hence, these cells, defined as pontine precursor-like cell (PPC), could be the cells of origin of DIPg [30] . PPCs express nestin, Olig2 and SOX2, but not gFAP [30] . The DIPg immunophenotype is very similar, but typically exhibits gFAP immunopositivity [30] . Interestingly, the murine pontine tumors also revealed the Nestin + /Olig2 + /SOX2 + /gFAP − phenotype [30] (Fig. 3a) . The m-VU-DIPg-3 and -5 tumors did not exhibit NeuN/Synaptophysin immunopositivity, arguing against a neuronal origin of these neoplasms (Fig. 3b) . Consistent with previous reports [30, 54] , the h-VUDIPg-3 and -5 primary tumor, while exhibiting cells that are nestin + /Olig2 + , also exhibited a high percentage of gFAP + cells (Fig. 3c) . Intriguingly, almost all m-VU-DIPg-3 and -5 cells were CD68+ and CD45+, as detected by IHC (Fig. 3d) and flow cytometry analysis (Fig. 3e, left panel) . In addition, approximately 7 % of the m-VU-DIPg-3 and -5 cell population resulted positive for CD11b (Fig. 3e, left panel) , indicating that these cells not only exhibit an immunophenotype characteristic of neural precursor cells but also characteristic of microglia/macrophages [40] . Next, we tested m-CNMC-D1 cells and h-SU-DIPg-VI cells for the presence of microglia/macrophage markers, and, while both were negative for CD45, they did present a subpopulation of cells positive for CD11b, 16 and 19 %, respectively (Fig. 3e, central and  right panel) . In line with this evidence, h-SU-DIPg-VI xenografts exhibited cells positive both for Human Nuclei antibody and CD68 (Fig. 3d, right panel) . Finally, we stained six human DIPg postmortem tissue samples (supplementary Table 1 ) for CD45 (marker for inflammatory cells), CD68, CD163 (marker for microglia/macrophages) and CD3 (marker for T-cells). While only few cells were positive for CD45 and CD3, a significant number of CD68 and CD163 positive cells were found within the tumor parenchyma (Fig. 3f) .
Discussion
DIPg, with a 2-year overall survival rate <2 %, is a pediatric brain malignancy with the worst prognosis. In the last 30 years, significant improvement in survival has been achieved in other pediatric cancers, while no progress has been made for children affected by DIPg, despite numerous clinical trials [22] . We have now made progress due to a focused effort to obtain tissue for research and the establishment of new experimental model systems. recent studies have demonstrated that DIPg is molecularly distinct from not only adult, but also pediatric supratentorial gliomas [1, 34, 35, 43, 49, 55] . Moreover, a specific, recurrent mutation in histone 3 at lysine 27 (H3 K27M) affecting the H3F3A gene (histone 3.3) or the HIST1H3B (histone 3.1) gene is found in nearly 80 % of DIPg tumors [23, 43, 49, 53] . Thalamic high-grade gliomas of childhood share this specific recurrent K27M point mutation in histone 3.1 or 3.3 genes, while pediatric cortical high-grade glioma exhibit a similarly specific histone 3 mutation at a different site [43, 49] . elegant studies have demonstrated that the recurrent histone 3 K27M mutation results in global loss of function of eZH2, a critical component of the epigenetic machinery responsible for trimethylation of lysine 27 in the N-terminal tail of the histone, along with broad changes in the epigenetic landscape [3, 26] . Yet, further research is needed to fully understand how these epigenetic changes are linked to DIPg tumorigenesis. Strikingly, DIPg presents in a specific temporal window, peaking in incidence at 6-9 years of age [30] and in a specific anatomical area (the ventral pons) [12] . Hence, not only its genetic composition, but also the pontine microenvironment at mid-childhood may account for the aggressive growth pattern and resistance to therapy this cancer exhibits.
given the urgent need for translational studies on DIPg, we set out to develop models for this disease using postmortem DIPg tissue [7, 30] . The direct method was attempted to avoid loss of putative important microenvironment growth factors after in vitro culture [31, 48] ; the indirect method was used to allow DIPg cell expansion. Interestingly, all tumors developed in the murine pons, and only in one case in the striatum, but none subcutaneously. This observation may provide further evidences of the importance of the brain and particularly of the pontine microenvironment in facilitating DIPg tumor growth. At two independent institutions, all tumors developed after direct injection of DIPg cells (without in vitro expansion) proved to be of murine and not of human origin, signifying that human DIPg cells, via mechanisms still to be elucidated, induced transformation of healthy murine brain cells into malignant ones. Conversely, h-SU-DIPg-VI cells, expanded in vitro before in vivo xenotransplantation, gave rise to tumors of human origin. To prove that the indirect method consistently allows development of human DIPg xenografts, the direct and indirect methods need to be tested in parallel on the same postmortem DIPg cells. Of note, although we performed different control experiments with postmortem tissue not affected by brain cancer, we cannot exclude that development of murine tumors could also occur after injection of other glioma or other non-brain cancer cells. While h-SU-DIPg-VI cells resulted negative for the H-2K d , a murine marker, not all murine neoplastic cells resulted positive; it has been reported that H-2K d is absent in murine neural stem cells [20, 28] .
Clearly, these findings raise multiple mechanistic questions.
Although not yet described for DIPg tumors, the occurrence of mouse tumors after injection of human tumor cells has been previously reported as a sporadic event [2, 15, 17, 18, 41, 45, 46, 51] and may be attributable to viral transformation [2] , human growth factor stimulation [50] , cell fusion [13, 14, 16, 17] or transference of human DNA into the mouse host cells [18] . Such events may lead to single catastrophic events causing the rapid and reproducible onset of mouse DIPg tumors as observed here [47] . It is unique to this study that, in all cases attempted with the direct xenotransplantation method, a murine and not a human tumor developed [9, 11, 27, 33, 36] . Different reports have demonstrated the presence of human DNA [18] and even human protein expression [17] in cancer cells with the genetic background of the host species [32] . In our studies we did not find any evidence of human genes or proteins in the murine neoplasms, possibly due to limitations of the methods employed. Thus, alternative approaches, such as whole genome sequencing, and analysis of the original xenografts, which developed directly after human cell injection, are warranted. A previous study, in which human gBM cells induced transformation of host hamster cells, reported that human chromosomes were segregated within the first transplant generation [17] .
Finally, the murine neoplasm exhibited microglia/macrophage markers, as did approximately 20 % of the h-SUDIPg-VI cells. Hence, we analyzed postmortem DIPg tissue and identified microglia/macrophages in the tumor parenchyma. Although there are no reports yet evaluating these cell types in the DIPg microenvironment, studies have shown that cells expressing microglia/macrophage markers comprise 30-50 % of the cells in benign and malignant gliomas [40] . While the role of microglia/macrophages in glioma has been controversial [52] , recent studies have demonstrated that pharmacologic and genetic inhibition of microglial/macrophage function reduces tumor growth in experimental rodent glioma models [25, 29, 37] , and the inhibition of colony stimulating factor-1 receptor has been shown to block glioma progression in a transgenic mouse model of proneuronal gBM [39] . Intriguingly, it has been hypothesized that microglia/macrophages in the glioma microenvironment may be malignant cells themselves and, given their ameboid properties, may be capable of invading the surrounding parenchyma giving rise to tumor growth and even tumor metastasis [21] .
In conclusion, this study highlights the need for diligent precaution when employing DIPg orthotopic xenograft models, and possibly other glioma and non-brain tumor models, to exclude a murine origin of the resulting tumor. It is tempting to speculate that this phenomenon may underscore a biological process relevant to the human disease; alternatively, this may be a phenomenon attributable to the altered immune function of the recipient immunodeficient mouse. The work presented here represents an important consideration for orthotopic xenograft models of DIPg, requiring careful species analysis to ensure that preclinical testing is performed in models as faithful to the human disease as possible.
